



18th Executive Board

6 - 7 June 2013

**WHO Headquarters, Salle A
Geneva, Switzerland**

Draft Resolution n° 10

Initiatives for the Paediatric ARV Market

The Board recognizes the importance of access to medicines for children living with HIV and reaffirms its commitment to addressing shortcomings in the market for paediatric ARVs.

The Board has therefore reviewed with interest the proposal, *Innovation in Paediatric Market Access (IPMA)*, submitted by the Clinton Health Access Initiative and the Partnership for Supply Chain Management.

In order to be in a position to decide whether to support the proposal, the Board instructs the Secretariat to secure further information on the key concerns raised by the Proposal Review Committee. In particular, the Board requires formal confirmation from the Global Fund that it is committed to procuring paediatric ARVs through this proposed mechanism and to co-funding the proposed initiative, with a view to the eventual transition of the project to the Global Fund. Alternatively the Board expresses its interest in receiving additional or a complementary proposal that can meet this objective. On this basis, the Board requests the Secretariat to present these proposals for a funding decision at the next Board session.

The Board also notes that the CHAI Paediatric ARV Project, the gains of which IPMA is designed to sustain, is currently scheduled to come to an end on 31 December 2013. The Board wishes to underline its strong commitment to avoiding any risk of stockouts for countries remaining within that project, pending transition. The Board therefore asks the Secretariat to assess the need for any extension of the Project into 2014, with a view to proposing a Board decision by e-vote before the next Board session, if necessary.

A handwritten signature in blue ink, appearing to read "P. Douste-Blazy". The signature is stylized and fluid.

Philippe Douste-Blazy
Chair of the UNITAID Executive Board